Hays Arnold

2.5k total citations · 3 hit papers
14 papers, 1.8k citations indexed

About

Hays Arnold is a scholar working on Surgery, Epidemiology and Genetics. According to data from OpenAlex, Hays Arnold has authored 14 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 6 papers in Epidemiology and 3 papers in Genetics. Recurrent topics in Hays Arnold's work include Liver Disease Diagnosis and Treatment (5 papers), Fibroblast Growth Factor Research (2 papers) and Eosinophilic Esophagitis (2 papers). Hays Arnold is often cited by papers focused on Liver Disease Diagnosis and Treatment (5 papers), Fibroblast Growth Factor Research (2 papers) and Eosinophilic Esophagitis (2 papers). Hays Arnold collaborates with scholars based in United States, Australia and Canada. Hays Arnold's co-authors include Stephen A. Harrison, Brent A. Neuschwander‐Tetri, D.R. Oliver, Soumya Gogia, Rohit Loomba, Lei Ling, Alex M. DePaoli, Stephen J. Rossi, Joel Z. Stengel and Marcelo Kugelmas and has published in prestigious journals such as The Lancet, Hepatology and Gut.

In The Last Decade

Hays Arnold

14 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease

2008 654 citations Stephen A. Harrison, D.R. Oliver et al. Gut profile →
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

2017 435 citations Rohit Loomba, Eric Lawitz et al. Hepatology profile →
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

2018 344 citations Stephen A. Harrison, Mary E. Rinella et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hays Arnold United States	9	1.3k	770	478	430	291	14	1.8k
Raffaella Vecchione Italy	15	871 0.7×	565 0.7×	252 0.5×	366 0.9×	260 0.9×	36	1.4k
Tarek Tamimi United States	6	1.1k 0.8×	637 0.8×	377 0.8×	159 0.4×	159 0.5×	17	1.3k
Meera Soni United States	3	1.3k 1.0×	778 1.0×	426 0.9×	195 0.5×	137 0.5×	4	1.4k
Bastiaan de Boer Australia	13	1.2k 0.9×	777 1.0×	350 0.7×	198 0.5×	157 0.5×	32	1.5k
Ēriks Šmagris United States	8	1.6k 1.2×	375 0.5×	827 1.7×	217 0.5×	314 1.1×	9	1.8k
Satoru Yatsuji Japan	13	1.1k 0.8×	661 0.9×	353 0.7×	178 0.4×	93 0.3×	22	1.2k
Gillian Patman United Kingdom	8	754 0.6×	446 0.6×	274 0.6×	105 0.2×	198 0.7×	43	1.0k
Shehan Abeygunasekera Australia	4	995 0.7×	268 0.3×	560 1.2×	219 0.5×	147 0.5×	5	1.1k
Narcissus Teoh Australia	12	529 0.4×	323 0.4×	177 0.4×	280 0.7×	361 1.2×	17	1.1k
Maria Antonella Burza Sweden	15	665 0.5×	240 0.3×	401 0.8×	252 0.6×	106 0.4×	21	985

Countries citing papers authored by Hays Arnold

Since Specialization

Citations

This map shows the geographic impact of Hays Arnold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hays Arnold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hays Arnold more than expected).

Fields of papers citing papers by Hays Arnold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hays Arnold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hays Arnold. The network helps show where Hays Arnold may publish in the future.

Co-authorship network of co-authors of Hays Arnold

This figure shows the co-authorship network connecting the top 25 collaborators of Hays Arnold. A scholar is included among the top collaborators of Hays Arnold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hays Arnold. Hays Arnold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Harrison, Stephen A., Mary E. Rinella, Manal F. Abdelmalek, et al.. (2018). NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 391(10126). 1174–1185. 344 indexed citations breakdown →

Mayo, Marlyn J., Alan Wigg, Barbara Leggett, et al.. (2018). NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial. Hepatology Communications. 2(9). 1037–1050. 107 indexed citations

Loomba, Rohit, Eric Lawitz, Parvez Mantry, et al.. (2017). The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 67(2). 549–559. 435 indexed citations breakdown →

Harrison, S.A., Manal F. Abdelmalek, J.F. Trotter, et al.. (2017). NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients. Journal of Hepatology. 66(1). S92–S93. 14 indexed citations

Poordad, Fred, Vinod K. Rustgi, Robert S. Brown, et al.. (2015). The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). Therapeutic Advances in Gastroenterology. 8(5). 263–269. 1 indexed citations

Arnold, Hays, et al.. (2010). An interesting case of iron deficiency anemia. Gastrointestinal Endoscopy. 72(1). 189–190. 1 indexed citations

Arnold, Hays, et al.. (2010). Routine screening for eosinophilic esophagitis in patients presenting with dysphagia. Therapeutic Advances in Gastroenterology. 4(1). 27–35. 41 indexed citations

Stengel, Joel Z., et al.. (2009). Infliximab: A Review of its Use in the Treatment of Crohn's Disease. 1. CMT.S2250–CMT.S2250. 1 indexed citations

Stengel, Joel Z. & Hays Arnold. (2008). Is infliximab safe to use while breastfeeding?. World Journal of Gastroenterology. 14(19). 3085–3085. 65 indexed citations

10.

Harrison, Stephen A., D.R. Oliver, Hays Arnold, Soumya Gogia, & Brent A. Neuschwander‐Tetri. (2008). Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 57(10). 1441–1447. 654 indexed citations breakdown →

11.

Arnold, Hays, et al.. (2005). Safety of band ligator use in the small bowel and the colon. Gastrointestinal Endoscopy. 62(2). 224–227. 35 indexed citations

12.

Arnold, Hays & Stephen A. Harrison. (2005). New Advances in Evaluation and Management of Patients with Polycystic Liver Disease. The American Journal of Gastroenterology. 100(11). 2569–2582. 77 indexed citations

13.

Lengfelder, Eva, et al.. (1988). [Familial polyglobulism--a rare differential diagnosis of polycythemia vera].. PubMed. 83(11). 363–6. 4 indexed citations

14.

Arnold, Hays, et al.. (1978). Kontrollierte Desferrioxamin-Therapie bei kongenitaler Anämie und Transfusionssiderose. DMW - Deutsche Medizinische Wochenschrift. 103(31). 1240–1244. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact